Prolexys and Columbia Publish Study On Erastin Mechanism of Action
 
Prolexys Pharmaceuticals and Columbia University this week announced a publication describing the properties of erastin, a selective small-molecule anti-tumor agent.
 
Prolexys and Columbia applied Prolexys’ chemi-proteomics technology to understand erastin’s mechanism of action. They found that erastin binds to mitochondrial voltage-dependent anion channels — a novel target for anti-cancer drugs.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.